Supplements
Low-sodium oxybate reduces daytime sleepiness and improves nighttime sleep in participants with narcolepsy
In a phase 4 open-label study of 34 participants with narcolepsy (type 1 or 2), low-sodium oxybate (LXB) significantly reduced daytime sleepiness, with a least-squares mean change in Epworth Sleepiness Scale score of -7.7 (P < 0.0001). Nighttime sleep improvements included a 45-minute increase in deep sleep (N3 duration), a reduction in transitions to lighter sleep stages by 13.1, and 3.2 fewer nocturnal awakenings.
Evidence Score
Evidence Score34/100
Human RCT
Meta-analysis
Mechanism
Safety
Confidencelow
Study Evidence
Study 1. Effectiveness and Safety of Low-Sodium Oxybate in Participants with Narcolepsy: Primary Results from the DUET Study.
observationalSchneider LD, Ruoff CM, Plante DT, Nichols DA, Steininger TL, Fuller DS, Kirby MT, Akerman S, Alexander JK, Whalen M, Cairns A · Neurology and therapy (2026)
Participants: N/A
Duration: 5-12 weeks (2-8 week titration + 2-week stable dose)
Intervention: Low-sodium oxybate (LXB; Xywav) with dose titration over 2-8 weeks followed by a 2-week stable-dose period
Outcome: Epworth Sleepiness Scale (ESS) score, nocturnal polysomnography measures (transitions to lighter sleep, N3 duration, nocturnal awakenings), Narcolepsy Severity Scale (NSS/NSS-2), Patient Global Impression of Severity and Change, sleep quality eDiaries, cataplexy attacks (NT1 only)
Effect Size: ESS change: -7.7 (SE 0.9); N3 duration increase: 45.0 min (SE 8.8); nocturnal awakenings decrease: -3.2 (SE 0.9); NSS change (NT1): -19.7 (SE 2.7); NSS-2 change (NT2): -11.3 (SE 1.6)
Population: Participants with narcolepsy type 1 (NT1, n=16) or type 2 (NT2, n=18) who completed the study (total n=34)
Result:
Mechanism Graph
LXB contains calcium, magnesium, potassium, and sodium oxybates
↓
Oxybate acts on GABA-B receptors to promote slow-wave sleep
↓
Reduced transitions to lighter sleep stages and fewer nocturnal awakenings
↓
Result: Increased deep sleep duration and reduced daytime sleepiness
Limitations
- ⚠Open-label design without a placebo control group limits causal inference
- ⚠Small sample size (n=34 completers) and short treatment duration (5-12 weeks) may not reflect long-term effects
Products
Affiliate links coming soon. We only recommend products that match the doses and forms used in the cited research.
References
- 1.Schneider LD, Ruoff CM, Plante DT, Nichols DA, Steininger TL, Fuller DS, Kirby MT, Akerman S, Alexander JK, Whalen M, Cairns A. "Effectiveness and Safety of Low-Sodium Oxybate in Participants with Narcolepsy: Primary Results from the DUET Study.." Neurology and therapy, 2026. PMID: 42060037 DOI: 10.1007/s40120-026-00921-3
Disclaimer: This content is for educational purposes only and is not medical advice. Evidence scores reflect the quality and quantity of available research, not clinical recommendations. Always consult a healthcare professional before starting any supplement or intervention.